Oxford Biomedica signs new deal to make AstraZeneca COVID shot – Times of India

London: Britain‘s oxford biomedica said on Friday it had signed a new three-year deal to build astraZenecaKovid-19 vaccine beyond 2022.
Oxford Biomedica, whose commitment under the previous deal for AstraZeneca’s vaccine will expire at the end of 2022, said it expected a record nearly £30 million ($36.4 million) in revenue from the contract in the current fiscal year.